AK138D1 vs Nezutatug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline

AK138D1

Developed by Akeso

Phase 1/2 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07623356 (registry estimate)

No aligned efficacy figure on record for this race.

Nezutatug

Developed by Hummingbird Bioscience

Phase 1/2 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05057013 · Phase 1/2 · active, not recruiting

The trial has no randomization, no blinding, and no control or comparator arm — it is a dose-escalation safety study designed to find a tolerable dose, not to test efficacy against a comparator. While outside reporting shows no dose-limiting toxicities were seen across six dose cohorts, this is a single-arm safety observation with no statistical comparison, so it cannot count as strong or even moderate clinical evidence of efficacy.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05910827 (registry estimate)

Reported efficacy

Number of Participants Who Experienced Dose Limiting Toxicities (DLTs); Part A (From first dose onwards until completion of Cycle 1 (28 days)); Number of Participants Who Experienced DLTs; Part B Arm 1 (From first dose of combination therapy onwards until completion of Cycle 1 (28 days)); Number of adverse events (AEs) by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1) (From the date of written informed consent until the end of the safety follow-up period (maximum [max] 42 weeks per participant)); Number of Grade 3, 4 and 5 AEs by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1) (From the date of written informed consent until the end of the safety follow-up period (max 42 weeks per participant)); Overall response rate (ORR) within 6 cycles of HMBD-001 (Part B Arm 1) (From baseline radiological disease assessment until 28 days after last dose of HMBD-001 (max 36 weeks per participant)): HMBD-001 (NCT05057013), Part A dose escalation: cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs). (not_applicable)

Result source: NCT05057013

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAK138D1Nezutatug
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

AK138D1
—Not reported
Nezutatug
—Not reported

OS, median

AK138D1
—Not reported
Nezutatug
—Not reported

ORR

AK138D1
—Not reported
Nezutatug
—Not reported

Duration of response, median

AK138D1
—Not reported
Nezutatug
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AK138D1: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nezutatug
HMBD-001 (NCT05057013), Part A dose escalation: cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs). NCT05057013 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AK138D1's landscape · Nezutatug's landscape